Historical overview and background
Origin and structure of the LBI HO
Partner | Joineda (Year) | Major Contributions to the LBI HO Consortium |
---|---|---|
Medical University of Vienna | 2008 | Clinical models, research labs, flow cytometry unit, student education, secretary office, CCC and VCSCC |
Hanusch Hospital, Vienna | 2008 | Clinical models, clinical trials, MDS, MPN and AML center |
University of Veterinary Medicine Vienna | 2017 | Mouse xenotransplantation models (NSG and NSG-related mouse strains), comparative oncology—focus: canine mast cell tumors |
Children’s Cancer Research Institute | 2018 | Molecular diagnostics—focus: Ph+ CML and MPN, mutation specific PCR assays—focus: BCR::ABL1 mutant forms |
Major aims and project lines in the LBI HO
Disease Model | Abbreviation | Phenotype of Stem Cell- Containing Cell Fractiona |
---|---|---|
Premalignant Neoplasms/Chronic Myeloid Neoplasms: | ||
Myelodysplastic neoplasms | MDSb | CD34+ |
Chronic myeloid leukemia | CML | CD34+/CD38−/CD26+/IL-1RAP+ |
Chronic myelomonocytic leukemia | CMML | CD34+/CD38− |
Ph− myeloproliferative neoplasms | MPNc | CD34+/CD38− |
Indolent systemic mastocytosis | ISMd | CD34+ |
Smoldering systemic mastocytosis | SSMd | CD34+ |
Aggressive Neoplasms/Acute Leukemiase: | ||
De novo acute myeloid leukemia | AML | CD34+ |
Secondary acute myeloid leukemia | sAML | CD34+ |
Ph+ Acute lymphoblastic leukemia | Ph+ ALL | CD34+ |
Ph− Acute lymphoblastic leukemia | Ph− ALL | CD34+ |
Acute mast cell leukemia | MCL | CD34+/CD38− |
Concept | Disease Model(s) |
---|---|
LSC eradication by allo-HSCT | Myeloid neoplasms, advanced mastocytosisa |
LSC eradication by LSC-directed drugs and drug combinations | Myeloid neoplasms, advanced mastocytosis |
Diagnostic LSC phenotyping and monitoring of MRD | CML, Ph+ ALL, AML, advanced mastocytosis |
Employing LSC markers and targets for improved prognostication and prediction of treatment responsesb | Myeloid neoplasms, mastocytosis |
Promoting personalized precision medicine approaches and tools from bulk cell- to LSC-assessment | Myeloid neoplasms, advanced mastocytosis |
Genetic predisposition and related germ line abnormalities/mutations | Myeloid neoplasms, mastocytosis, mast cell activation syndromes (MCAS) |
Mast cell eradication to cure MCAS | Mastocytosis with MCAS (primary MCAS), secondary MCAS, idiopathic MCAS |
Open Innovation in Science (OIS) | Myeloid neoplasms, mastocytosis, MCAS |
Comparative Oncology/Hematology | Human and canine mast cell neoplasms |
Examples of contributions of the LBI HO to basic LSC research
Identification of ‘stem cell signatures’ in patients with premalignant clonal conditions and patients with minimal residual disease during therapy
Identification of specific aberrant (diagnostic) phenotypes of LSC in myeloid leukemias
Identification of the osteoblast as a major site of LSC resistance in ph+ CML
The BRD4-MYC axis as a driver of LSC resistance in myeloid neoplasms
Examples of contributions of the LBI HO to clinical translation
From KIT to KIT-targeting treatment concepts
Identification of CDK4/CDK6 as key vulnerability of BCR::ABL1 T315I-transformed cells
Dissection of niche-targeting effects of BCR::ABL1-directed TKI
Immunotherapies directed against LSC to improve curative treatment approaches
Major conferences and other meetings organized by the LBI HO
Title and Topic of Meetinga | Place & Year | Publicationb |
CSC Symposium 2008 | Vienna 2008 | – |
Year 2011 Working Conference on CSC | Vienna 2011 | |
10 Year Jubilee Meeting of the VCSCC | Vienna 2012 | [not listedc] |
Ph+ CML: from LSC Eradication to Cure | Vienna 2014 | – |
From Cellular Basis and Targets to Targeted Therapies | Vienna 2015 | [77] |
Classification and Nomenclature of Clonal Conditions | Vienna 2015 | [77] |
Workshop on MDS and pre-MDS Conditions | Vienna 2016 | [not listed] |
10 Year Jubilee Meeting of the LBC ONC | Vienna 2018 | [46] |
Working Conference on CMML | Vienna 2018 | [not listed] |
Precision Medicine in Hematology Meeting | Vienna 2019 | [not listed] |
Cell Therapies and Stem Cells in AML and CML | Vienna 2020 | [45] |
20 Year Jubilee Meeting of the VCSCC | Vienna 2022 | [47] |
15 Year Jubilee Meeting of the LBI HO | Vienna 2023 | This document |